Posted on October 23, 2015 by GlycoMark USA
Upcoming webinar by the American Association for Clinical Chemistry (AACC) warns of variants and adducts that may affect accuracy of A1c tests New York, NY (October 23, 2015) – An upcoming webinar hosted by the AACC will discuss potential pitfalls of the hemoglobin A1c test due to conditional interferences that can affect the accuracy…
Read More
Posted on October 23, 2015 by GlycoMark USA
NEW YORK, NY (October 23, 2015) – In a new study published by the medical journal Diabetes involving more than 11,000 subjects, the GlycoMark test was used to help define links between hyperglycemic excursions and increased incidence of cardiovascular disease and death1. The recently published study involved analysis from the Atherosclerosis Risk In Communities (ARIC)…
Read More
Posted on October 17, 2015 by GlycoMark USA
Agreement Facilitates Greater Accessibility For Patients and Clinicians of Important Diabetes Test New York, NY (October 17, 2015) – Glycomark, Inc., the United States commercialization channel for the Glycomark test, announced today that their assay for diabetes will be marketed nationwide through a partnership with BioReference Laboratories. The Glycomark® test is a clinically proven,…
Read More
The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.